Company Overview
Snapshot
Founded in May 2012 by Ofer Yodfat and Guy Shinar, Javelin Medical operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on developing its Vine device for stroke prevention. Its product, Vine, is undergoing clinical trials, specifically available through participation in the CAPTURE II study in several European countries.
Business overview
Javelin Medical is a Health Tech & Life Sciences company developing medical devices to prevent stroke in individuals with atrial fibrillation. Its core product, Vine, is a permanent filter designed for implantation in the carotid arteries to intercept blood clots. The device is implanted through a thin needle in a short procedure and is currently being evaluated in clinical trials. Javelin Medical serves the healthcare industry, targeting healthcare providers, doctors, clinics, and hospitals within the cardiology and neurology sectors, with a business model focused on B2B interactions.
Strategic signal
In May 2019, Javelin Medical's novel carotid filter for stroke prevention in Afib was highlighted, indicating the company's focus on addressing a critical medical need. This signals a commitment to advancing medical device technology for cardiovascular health, positioning Javelin Medical as a potential innovator in stroke prevention strategies.
Log in to access full profile ›Company Intelligence Q&A
- What is Javelin Medical's primary focus?
- Javelin Medical is focused on developing a medical device to prevent stroke in individuals with abnormal heart rhythm (atrial fibrillation).
- What is the name of Javelin Medical's core product?
- Javelin Medical's core product is Vine, a permanent filter designed for implantation in the carotid arteries.
- When was Javelin Medical founded?
- Javelin Medical was founded in May 2012.
- Who are the founders of Javelin Medical?
- Javelin Medical was co-founded by Ofer Yodfat and Guy Shinar.
- In which regions is Javelin Medical's Vine device currently available?
- The Vine device is currently available for individuals with atrial fibrillation through participation in the CAPTURE II study in several European countries.